BenevolentAI S.A. (2XA.F)

0,6400 -0,0320 (-4,76%) Al cierre: 03:29PM CEST

BenevolentAI S.A.

4-8 Maple Street
London W1T 5HD
United Kingdom
44 20 3781 9360
https://www.benevolent.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 248

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Joerg Moeller M.D., Ph.D.	CEO & Executive Director	N/A	N/A	N/A
Dr. Ivan Griffin Ph.D.	Co-Founder	349,2k	N/A	N/A
Ms. Catherine Isted A.C.M.A.	Chief Financial Officer	N/A	N/A	1975
Dr. James Malone	Chief Technology Officer	N/A	N/A	N/A
Dr. Anne Phelan	Chief Scientific Officer & Site Head for the Benevolent Cambridge Laboratories	352,87k	N/A	N/A
Ms. Fleur Wood	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Will Scrimshaw	General Counsel & Company Secretary	N/A	N/A	N/A
Ms. Anna Fullerton-Batten	Chief People Officer	N/A	N/A	N/A
Mr. Tom Holgate	Senior Vice President of Finance	N/A	N/A	N/A
Ms. Christina Busmalis	Chief Revenue Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

Gobierno corporativo

El ISS Governance QualityScore de BenevolentAI S.A., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.